Korro Bio (KRRO) announced that it has been granted orphan drug designation by the European Medicines Agency Committee, who adopted a positive opinion on KRRO-110, Korro's investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency.
"The EMA orphan drug designation for KRRO-110 is a significant milestone for Korro and highlights an urgent need to bring innovative solutions to people with AATD seeking new, disease-modifying therapies," said Kemi Olugemo, Chief Medical Officer at Korro.
In March 2025, KRRO-110 received orphan drug designation from the U.S. FDA for the treatment of AATD.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.